News
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

36,465 Results

Type

Article (2343)
Company Profile (36)
Press Release (34086)

Section

Business (14010)
Career Advice (74)
Deals (2066)
Drug Delivery (6)
Drug Development (4045)
Employer Resources (10)
FDA (422)
Job Trends (751)
News (19948)
Policy (1047)

Tag

Date

Today (1)
Last 7 days (27)
Last 30 days (138)
Last 365 days (2893)
2024 (1631)
2023 (2859)
2022 (3751)
2021 (4051)
2020 (3471)
2019 (2061)
2018 (1554)
2017 (1795)
2016 (1624)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)

Filters

Type

Article (2343)
Company Profile (36)
Press Release (34086)

Section

Business (14010)
Career Advice (74)
Deals (2066)
Drug Delivery (6)
Drug Development (4045)
Employer Resources (10)
FDA (422)
Job Trends (751)
News (19948)
Policy (1047)

Tag

Date

Today (1)
Last 7 days (27)
Last 30 days (138)
Last 365 days (2893)
2024 (1631)
2023 (2859)
2022 (3751)
2021 (4051)
2020 (3471)
2019 (2061)
2018 (1554)
2017 (1795)
2016 (1624)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)

36,465 Results for "sagimet biosciences".

Sort By

Business

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Sagimet Biosciences Inc. announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024.

May 6, 2024
·
7 min read
Business

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended March 31, 2024, and provided recent corporate updates.

May 15, 2024
·
8 min read
Drug Development

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Sagimet Biosciences Inc. announced that it will host a conference call and webcast on Thursday, June 13, 2024, at 9.30 AM PT / 12:30 PM ET.

June 10, 2024
·
8 min read
Drug Development

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT) today announced the completion of a Phase 1 hepatic impairment study with denifanstat, a selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

March 27, 2024
·
5 min read
Biotech Bay

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

Sagimet Biosciences Inc. today announced it will host a virtual investor and analyst day on Thursday, May 23, 2024 at 1:00 PM ET.

May 16, 2024
·
7 min read
Business

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Sagimet Biosciences Inc. today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024.

March 25, 2024
·
8 min read
Drug Development

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Sagimet Biosciences Inc. presented positive data from its FASCINATE-2 Phase 2b clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic dysfunction-associated steatohepatitis patients at the European Association for the Study of the Liver Congress being held in Milan, Italy.

June 6, 2024
·
10 min read
Biotech Bay

Sagimet Biosciences to Participate in Two Upcoming March 2024 Investor Conferences

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic and fibrotic pathways, announced that management will participate in two upcoming investor conferences.

February 29, 2024
·
1 min read
Business

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic and fibrotic pathways, reported financial results for the full year ended December 31, 2023, and provided corporate updates.

March 25, 2024
·
11 min read
Biotech Bay

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic and fibrotic pathways, announced it will host a virtual investor and analyst day on Friday, May 3, 2024 at 12:30 PM ET.

April 22, 2024
·
6 min read

1 of 3,647

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
Hotbeds
About
More

© 1985 - 2024 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin